142 related articles for article (PubMed ID: 37914483)
1. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T; Papayannidis C; Demirkan F; Doronin V; Fogliatto LM; Guttke C; Gyan E; Hamad N; Herrera P; Hultberg A; Jacobs J; Johnson AJ; Langlois A; Ma X; Martinelli G; Arnan M; Müller R; Nottage K; Ofran Y; Özcan M; Samoilova O; Tolbert JA; Trudel GC; Xiu L; Vey N; Wei AH
Lancet Haematol; 2023 Nov; 10(11):e902-e912. PubMed ID: 37914483
[TBL] [Abstract][Full Text] [Related]
2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
3. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
4. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T; Vey N; Adès L; Bacher U; Bargetzi M; Fung S; Gaidano G; Gandini D; Hultberg A; Johnson A; Ma X; Müller R; Nottage K; Papayannidis C; Recher C; Riether C; Shah P; Tryon J; Xiu L; Ochsenbein AF
Haematologica; 2023 Jul; 108(7):1793-1802. PubMed ID: 36779592
[TBL] [Abstract][Full Text] [Related]
5. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
6. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
[TBL] [Abstract][Full Text] [Related]
7. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Garcia-Manero G; Goldberg AD; Winer ES; Altman JK; Fathi AT; Odenike O; Roboz GJ; Sweet K; Miller C; Wennborg A; Hickman DK; Kanagal-Shamanna R; Kantarjian H; Lancet J; Komrokji R; Attar EC; Sallman DA
Lancet Haematol; 2023 Apr; 10(4):e272-e283. PubMed ID: 36990622
[TBL] [Abstract][Full Text] [Related]
8. Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.
Ikezoe T; Usuki K; Aida K; Hatayama T; Shirahase T; Yamauchi T
Cancer Sci; 2023 Mar; 114(3):1037-1044. PubMed ID: 36394119
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
10. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
12. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
15. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
17. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
[TBL] [Abstract][Full Text] [Related]
18. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
[TBL] [Abstract][Full Text] [Related]
19. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M; Wijermans PW; Kicinski M; Chantepie S; Van der Velden WJFM; Noppeney R; Griškevičius L; Neubauer A; Crysandt M; Vrhovac R; Luppi M; Fuhrmann S; Audisio E; Candoni A; Legrand O; Foà R; Gaidano G; van Lammeren-Venema D; Posthuma EFM; Hoogendoorn M; Giraut A; Stevens-Kroef M; Jansen JH; de Graaf AO; Efficace F; Ammatuna E; Vilque JP; Wäsch R; Becker H; Blijlevens N; Dührsen U; Baron F; Suciu S; Amadori S; Venditti A; Huls G;
Lancet Haematol; 2023 Nov; 10(11):e879-e889. PubMed ID: 37914482
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Taniguchi S; Yamauchi T; Choi I; Fukuhara N; Potluri J; Salem AH; Hong WJ; Honda H; Nishimura Y; Okubo S; Usuki K
Jpn J Clin Oncol; 2021 May; 51(6):857-864. PubMed ID: 33712849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
